Study Of The Antiischemic Action Of EGb 761 In The Treatment Of Peripheral Arterial Occlusive Disease By TcPo2 Determination

Effect None
Trial Design Double blind
Trial Length 2-4 Weeks
Number of Subjects 20
Sex Both Genders
Age Range 45-64, 65+
Notes for this study:
In persons with peripheral arterial occlusive disease given 160mg EGb-761 twice daily for a period of 4 weeks, supplementation failed to improve performance on a treadmill test (intermittent claudication) but was effective in reducing the degree of cerebral ischemia associated with exercise. No differences were noted at rest.

Full details on all 6 studies are available to Examine memberstry free for 7 days.

Already a member? Log in now to access.